Bispecific binding agents
By designing a bispecific binding agent that can bind both F-actin and Fc receptors, the problem of insufficient antigen processing capacity of immune cells in the prior art to necrotic cell is solved, and a wider and stronger anti-tumor immune response is achieved.
CN119731210APending Publication Date: 2025-03-28THE FRANCIS CRICK INST LTD
3 Cites 0 Cited by
Patent Information
- Application Number
- CN202380044739.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-10-07
- Filing Date
- 2023-04-21
- Publication Date
- 2025-03-28
AI Technical Summary
Technical Problem
The prior art is difficult to effectively activate a variety of immune cells to induce and process antigens in necrotic cells, limiting the intensity and range of anti-tumor immune responses.
Method used
A bispecific binding agent was designed that combines the F-actin binding moiety and the Fc receptor binding moiety, allowing it to bind to both the F-actin and Fc receptors, thereby activating the responses of a variety of downstream immune cells, including cross-presentation, MHC class II presentation and cellular activation.
Benefits of technology
By expanding the type and number of APCs that can sense necrotic cell antigens, the intensity of the initiation and immune response of CD8+ T cells is enhanced, and anti-cancer immunity is promoted.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention relates to a bispecific binding agent for use in medicine, the bispecific binding agent comprising an F-actin binding moiety and an Fc domain, the bispecific binding agent allowing simultaneous binding of an Fc receptor and an F-actin. This allows necrotic cell antigens to be presented to the immune system. The invention also provides bispecific binding agents and methods of identifying tumor antigens using the agents.
Need to check novelty before this filing date? Find Prior Art